TY - JOUR
T1 - Association between serum values of C-reactive protein and cytokine production in whole blood of patients with Type 2 diabetes
AU - Castoldi, Giovanna
AU - Galimberti, Stefania
AU - Riva, Chiara
AU - Papagna, Ruggero
AU - Querci, Federico
AU - Casati, Marco
AU - Zerbini, Gianpaolo
AU - Caccianiga, Gianluigi
AU - Ferrarese, Carlo
AU - Baldoni, Marco
AU - Valsecchi, Maria Grazia
AU - Stella, Andrea
PY - 2007/7
Y1 - 2007/7
N2 - Diabetes mellitus accelerates atherosclerotic processes, and it is known that inflammation plays a key role in atherosclerosis. The aim of the present study was to evaluate in patients with Type 2 diabetes whether serum levels of CRP (C-reactive protein) are associated with cytokine production in whole blood. A total of 89 outpatients with Type 2 diabetes were enrolled, and blood pressure, body mass index, fasting blood glucose, glycated haemoglobin, cholesterol, triacylglycerols (triglycerides) and hs-CRP (high-sensitivity CRP) were measured. IL-6 (interleukin-6), IL-1β (interleukin-1β) and TNF-α (tumour necrosis factor-α) were measured before and after 24 h of incubation of whole blood with LPS (lipopolysaccharide) or saline. The basal values of IL-1β, IL-6 and TNF-α were low and were not significantly related to hs-CRP levels. A univariate analysis showed that the level of IL-1β and IL-6, obtained after 24 h of incubation of whole blood with LPS, increased significantly with increasing levels of hs-CRP and, after adjusting for potential confounders, IL-1β still remained statistically significant. In our sample of patients with Type 2 diabetes, there was no association between serum hs-CRP levels and basal levels of IL-6, IL-1β and TNF-α. Conversely, a significant association was observed between serum hs-CRP levels and IL-1β and IL-6 production after 24 h of incubation of whole blood with LPS. In conclusion, our data suggest that patients with Type 2 diabetes and high hs-CRP levels may have an enhanced reactivity in response to specific stimuli that produce different interleukins, with possible implications in inflammatory atherosclerotic processes.
AB - Diabetes mellitus accelerates atherosclerotic processes, and it is known that inflammation plays a key role in atherosclerosis. The aim of the present study was to evaluate in patients with Type 2 diabetes whether serum levels of CRP (C-reactive protein) are associated with cytokine production in whole blood. A total of 89 outpatients with Type 2 diabetes were enrolled, and blood pressure, body mass index, fasting blood glucose, glycated haemoglobin, cholesterol, triacylglycerols (triglycerides) and hs-CRP (high-sensitivity CRP) were measured. IL-6 (interleukin-6), IL-1β (interleukin-1β) and TNF-α (tumour necrosis factor-α) were measured before and after 24 h of incubation of whole blood with LPS (lipopolysaccharide) or saline. The basal values of IL-1β, IL-6 and TNF-α were low and were not significantly related to hs-CRP levels. A univariate analysis showed that the level of IL-1β and IL-6, obtained after 24 h of incubation of whole blood with LPS, increased significantly with increasing levels of hs-CRP and, after adjusting for potential confounders, IL-1β still remained statistically significant. In our sample of patients with Type 2 diabetes, there was no association between serum hs-CRP levels and basal levels of IL-6, IL-1β and TNF-α. Conversely, a significant association was observed between serum hs-CRP levels and IL-1β and IL-6 production after 24 h of incubation of whole blood with LPS. In conclusion, our data suggest that patients with Type 2 diabetes and high hs-CRP levels may have an enhanced reactivity in response to specific stimuli that produce different interleukins, with possible implications in inflammatory atherosclerotic processes.
KW - C-reactive protein (CRP)
KW - Cytokine
KW - Inflammation
KW - Insulin resistance
KW - Interleukin
KW - Lipopolysaccharide
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=34447498697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447498697&partnerID=8YFLogxK
U2 - 10.1042/CS20060338
DO - 10.1042/CS20060338
M3 - Article
C2 - 17362204
AN - SCOPUS:34447498697
VL - 113
SP - 103
EP - 108
JO - Clinical Science
JF - Clinical Science
SN - 0143-5221
IS - 1-2
ER -